Search Results for “EU” – Page 6 – media

Major Pharmaceutical Holdings’ Subsidiary for Traditional Chinese Medicine Officially Starts Production

On September 24, reporters from Dahe Finance learned through Major Pharmaceutical Holdings’ official WeChat account that recently, the opening ceremony for Chongqing Pharmaceutical Group Jiulong Modern Traditional Chinese Medicine Co., Ltd. (hereinafter referred to as “Zhongyao Jiulong”) was held in Nanchuan District, Chongqing City. Officials from relevant departments, including the Chongqing Economic and Information Commission, the Health Commission, and the Drug Administration, as well as leaders from the Nanchuan District Committee and District Government, attended the ceremony. Noteworthy attendees included Qiu Huaiwei, Secretary of the Party Committee and Chairman of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (hereinafter referred to as “China Resources Sanjiu”), and Yuan Quan, Secretary of the Party Committee and Chairman of Chongqing Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as “Zhongyao Group”). Zhongyao Jiulong was established in October 2020 through joint investment from Major Pharmaceutical Holdings’ subsidiary, Zhongyao Group, and China Resources Sanjiu. The company ...
- Source: drugdu
- 70
- September 26, 2024
Junshi Biosciences’ PD-1 Approved in the EU, Achieving Market Launch in China, the US, and Europe

As a result, Toripalimab has become the first and only PD-1 approved for the treatment of nasopharyngeal carcinoma in Europe, as well as the only first-line treatment drug for advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression. Prior to this, Toripalimab had already been approved in China and the US. On July 28, Junshi Biosciences announced that Toripalimab’s marketing authorization application received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending its approval for the aforementioned indications. Toripalimab injection (Chinese trade name: Tuoyi®) is the first domestically approved PD-1 monoclonal antibody in China. In December 2018, the National Medical Products Administration conditionally approved Toripalimab for the treatment of unresectable or metastatic melanoma in patients who had failed prior systemic therapy. As of now, Toripalimab has received approval for seven indications in China, covering the treatment of melanoma, nasopharyngeal carcinoma, ...
- Source: drugdu
- 101
- September 25, 2024
CHMP recommends H drug for EU market launch

Henlius Biopharmaceutical Editor September 23, 2024 09:21 Shanghai H drug Hans form ® It is the world’s first anti-PD-1 monoclonal antibody approved for first-line treatment of ES-SCLC H drug Hans form ® Expected to become the first and only anti-PD-1 monoclonal antibody marketed in Europe for first-line treatment of ES-SCLC H drug Hans form ® Currently approved for market in countries such as China, Indonesia, Cambodia, and Thailand, benefiting approximately 80000 patients On September 20, 2024, Fosun Pharma (2696. HK) announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the company’s independently developed anti-PD-1 monoclonal antibody H drug, Hansid ® (Sullimumab) has received positive approval for marketing authorization, and it is recommended to approve its indication for first-line treatment of extensive stage small cell lung cancer (ES-SCLC). In 2023, Fosun Pharma partnered with Intas to grant exclusive development and commercialization rights for ...
- Source: drugdu
- 76
- September 24, 2024
Domestic endoscopy giant acquires European counterparts

On September 18, Micro-Tech (NL) International B.V. announced that the company intends to use its own funds of no more than 36.72 million euros (equivalent to approximately 289 million yuan) to purchase 51% of the shares of Creo Medical S.L.U. (hereinafter referred to as “CME”) held by CreoMedical Group plc (hereinafter referred to as “Creo”) through its wholly-owned subsidiary Micro-Tech (NL) International B.V. After the completion of this transaction, CME will become a holding subsidiary of the company. The announcement shows that Creo is a medical device company headquartered in the UK and listed on the London Stock Exchange (stock code: CREO). Creo focuses on the development and commercialization of minimally invasive surgical equipment in the field of surgical endoscopy. Its main product is CROMA, an electrosurgical platform that can provide microwaves and bipolar radiofrequency for local cutting through a single accessory port, providing doctors with simplified and controllable surgical ...
- Source: drugdu
- 83
- September 24, 2024
Pneumonia Vaccine Price War Erupted

A price war has erupted for pneumonia vaccines, with pharmaceutical companies attempting to exchange lower prices for market share. Recently, public resource trading center websites in several provinces, including Jilin and Jiangsu, have shown that Zhifei Biological’s wholly-owned subsidiary, Zhifei Lvzhu, has reduced the price of its 0.5ml, 23-valent pneumococcal polysaccharide vaccine from 298 yuan to 209 yuan, a decrease of nearly 30%. This follows a series of price cuts for other vaccines, such as the HPV and flu vaccines, marking yet another manufacturer proactively lowering vaccine supply prices. Will other manufacturers follow suit? Watson Bio recently disclosed in a research announcement that the price of its 23-valent pneumonia vaccine has remained stable since its market introduction. Currently, the nationwide average winning bid price is lower than the adjusted prices of its competitors, and the company hopes to maintain price stability for its related products. Zhifei Biological’s 23-valent pneumococcal polysaccharide ...
- Source: drugdu
- 67
- September 20, 2024
1.5 billion US dollars! Capricor Therapeutics partners with Nippon Pharmaceutical Co., Ltd

Disclaimer: Due to limited proficiency, errors are inevitable, or some information may not be timely. Please feel free to leave a message to indicate. This article only provides an introduction to medical and health-related drugs, and does not recommend treatment plans (if applicable); This article does not constitute any investment advice. On September 17, 2024, Capricor Therapeutics, a biotechnology company developing transformed cell and exosome therapies for the treatment of rare diseases, announced that it had signed a binding term sheet with Nippon Pharma. The terms state that Nippon Pharma will commercialize and distribute Capricor’s main asset, deramiocel, in Europe for the treatment of Duchenne muscular dystrophy (DMD). Capricor will receive a $15 million equity investment at a 20% premium and a $20 million advance payment upon signing the final agreement. The potential milestone amount is as high as $715 million, with product revenue accounting for double digits. The total ...
- Source: drugdu
- 63
- September 19, 2024
National Drug Administration Advances the Development of Online Sales Monitoring Platform for Pharmaceuticals and Cosmetics

Vice Minister Huang Guo of the National Drug Administration recently revealed that the agency is leading the modernization of drug regulation through information technology. The administration continues to implement the Smart Drug Regulation Action Plan, focusing on building an integrated system for the registration and approval of drugs, medical devices, and cosmetics. This initiative aims to fulfill the “efficient handling of single transactions” requirement, achieving seamless cooperation throughout the entire process from acceptance and review to approval and certification. As a result, the volume of online acceptance and the rate of timely conclusions have steadily increased, significantly enhancing the quality and efficiency of reviews and approvals. Currently, all government service matters handled by the National Drug Administration have been transitioned to 100% online processing, and all enterprise-related certificates at the bureau level have been fully digitized. The total number of electronic certificates issued has exceeded 170,000, allowing enterprises to access ...
- Source: drugdu
- 60
- September 19, 2024
Leading the development of antibody drugs! Zhengda Tianqing Nanjing Shunxin Pharmaceutical was recognized as “Nanjing Engineering Research Center”

The “Nanjing Antibody Drug Screening and Transformation Engineering Research Center” built this time aims at the difficulties and pain points of key technologies and results transformation in the process of antibody drug research and development and industrialization. It will build and improve the two key platforms of “core technology breakthrough” and “innovation results transformation” to conduct independent localization research on materials and consumables required for the production of biological products, including cell culture medium, protein chromatography medium and virus removal nanofiltration membrane, and carry out results transformation and industrialization development for key innovative antibodies, antibody-drug conjugates and recombinant humanized proteins. Next, the “Nanjing Antibody Drug Screening and Transformation Engineering Research Center” will further promote the development of biological products and the joint development of upstream and downstream industrial chains, complete the transformation from biosimilars to innovative biological products, develop new antibody drugs with independent intellectual property rights, and ensure the ...
- Source: drugdu
- 123
- September 18, 2024
Increasing Investment in R&D Innovation to Deepen Product Competitive Moats

CSPC Pharmaceutical Group has achieved significant milestones in research and development, securing conditional approval for its self-developed Class 1 new drug, Enlansub, and for the injectable version of Rayzoprazole. The company has also received approval for clinical trials in the U.S. for its antibody-drug conjugate, clinical trial approval for its mRNA vaccine against respiratory syncytial virus, and clinical trial approval for the first CAR-T cell injection based on mRNA-LNP technology. As an innovation-driven enterprise and a key player in the national industrial chain, CSPC continues to enhance its R&D investments, elevate its international influence, and fortify its product competitive edge. This year, various in-development drugs have reached key progress points, with some approved for market launch or clinical trials both domestically and internationally. Currently, CSPC is conducting over 130 innovative drug projects, with more than 50 new drugs expected to be launched in the next five years. Comprehensive Market Coverage ...
- Source: drugdu
- 74
- September 14, 2024
A Chinese innovative pharmaceutical company “died”

On September 5, Connect (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company headquartered in the United States, announced its financial results for the six months ended June 30, 2024 and announced plans to large-scale attrition. In addition, as part of Connect’s transformation into a U.S.-focused company, the company plans to significantly reduce the scale of its operations in China. Just a few months ago, Connect was an innovative pharmaceutical company in China. All these changes are rooted in the clinical setbacks of Connect’s core pipeline product, Rademikibart (CBP-201). This is a fully human monoclonal antibody targeting IL-4Rα, which is a common subunit of IL-4Rα and IL-13 receptors. It directly targets Sanofi’s new autoimmune drug Duprilumab. anti. In the CBP-201 clinical data previously announced by Connect, although some connotations of long-term efficacy data were seen, the improvement in the 16-week data was weaker than that of dupilumab; in addition, because it was ...
- Source: drugdu
- 55
- September 13, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.